NEW YORK – Pathos AI on Thursday said it has licensed the PRMT5 inhibitor PRT811 from Prelude Therapeutics and hopes to improve on the compound's prior Phase I clinical trial response rates using a biomarker strategy developed on its artificial intelligence platform.
In the Phase I trial of PRT811 conducted by Prelude, among a group of 16 patients with IDH-positive, high-grade glioma, two patients had confirmed complete responses. As of the most recent follow-up, one of those responses was ongoing after 31 months, while the other had a duration of 7.5 months. Another patient had an unconfirmed partial response. In another group of 23 patients with uveal melanoma, one patient had a confirmed partial response lasting 10 months and another had an unconfirmed partial response. Both of those uveal melanoma patients had a splicing factor 3B subunit 1 mutation.
PRT811, which Chicago-based Pathos AI has renamed P-500, is a selective, brain-penetrant small-molecule inhibitor of PRMT5 that has potential as a treatment for a number of cancers whose growth depends on PRMT5.
"These results from Prelude's Phase I study are promising news for high-grade glioma patients and clinicians, who still have limited treatment options with chemotherapy and radiation that hasn't changed in decades," Pathos CEO Ryan Fukushima said in a statement. "With our AI platform, we aim to increase the already encouraging response rate of P-500 through a novel biomarker-driven strategy."